{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:10Z","timestamp":1786119370713,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/coc.0b013e31819cc9ed","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T20:33:53Z","timestamp":1259354033000},"page":"607-611","source":"Crossref","is-referenced-by-count":2,"title":["Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies"],"prefix":"10.1097","volume":"32","author":[{"given":"Daruka","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Dreisbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kristedja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yrma","family":"Obregon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1054\/bjoc.2000.1307","article-title":"Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer\u2013a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non\u2013small-cell lung Cancer.","volume":"83","author":"Anderson","year":"2000","journal-title":"Br J Cancer"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1200\/JCO.2000.18.12.2419","article-title":"Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.","volume":"18","author":"Rini","year":"2000","journal-title":"J Clin Oncol"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/1097-0142(20000601)88:11<2505::AID-CNCR11>3.0.CO;2-E","article-title":"A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.","volume":"88","author":"Ulrich-Pur","year":"2000","journal-title":"Cancer"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a010600","article-title":"A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.","volume":"7","author":"Rothenberg","year":"1996","journal-title":"Ann Oncol"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004836-200006000-00003","article-title":"Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas.","volume":"30","author":"Wiernik","year":"2000","journal-title":"J Clin Gastroenterol"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00685109","article-title":"Saturation of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.","volume":"27","author":"Grunewald","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1634\/theoncologist.2007-0215","article-title":"Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.","volume":"13","author":"Veltkamp","year":"2008","journal-title":"Oncologist"},{"issue":"suppl 10","key":"R11-8-20210128","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology andmechanism of action.","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1023\/A:1008487932384","article-title":"Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.","volume":"9","author":"Touroutoglou","year":"1998","journal-title":"Ann Oncol"},{"key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdl084","article-title":"A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.","volume":"17","author":"Soo","year":"2006","journal-title":"Ann Oncol"},{"key":"R15-8-20210128","first-page":"93","article-title":"In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma.","volume":"26","author":"Kreil","year":"1999","journal-title":"Acta Med Austriaca"},{"issue":"suppl 4","key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/annonc\/10.suppl_4.S234","article-title":"Experimental drugs and drug combinations in pancreatic cancer.","volume":"10","author":"Kroep","year":"1999","journal-title":"Ann Oncol"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.breast.2005.11.010","article-title":"Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I\/II study.","volume":"15","author":"Campone","year":"2006","journal-title":"Breast"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3109\/02841869509127192","article-title":"Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.","volume":"34","author":"Andersson","year":"1995","journal-title":"Acta Oncol"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1008232329498","article-title":"Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.","volume":"8","author":"Fetscher","year":"1997","journal-title":"Ann Oncol"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/bjc.1998.329","article-title":"Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.","volume":"77","author":"Chi","year":"1998","journal-title":"Br J Cancer"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000282576","article-title":"Trial with bacillus Calmette-Guerin and epirubicin combination in the prophylaxis of superficial bladder cancer.","volume":"52","author":"Erol","year":"1994","journal-title":"Urol Int"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.coc.0000128527.95562.ae","article-title":"Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.","volume":"27","author":"Hausmaninger","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1054\/bjoc.1999.1003","article-title":"Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study.","volume":"82","author":"van Putten","year":"2000","journal-title":"Br J Cancer"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2. 0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006121608414","article-title":"Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study.","volume":"16","author":"Luftner","year":"1998","journal-title":"Invest New Drugs"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0b013e31819cc9ed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:09:41Z","timestamp":1786039781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200912000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31819cc9ed","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}